Marker Therapeutics, Inc.MRKRNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-7.0%
5Y CAGR-2.7%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-7.0%/yr
vs -47.4%/yr prior
5Y CAGR
-2.7%/yr
Recent deceleration
Acceleration
+40.4pp
Accelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
TTM$9.12M+115.1%
2024$4.24M-43.3%
2023$7.48M-34.1%
2022$11.34M-69.8%
2021$37.56M+258.6%
2020$10.47M+5.0%
2019$9.98M-93.3%
2018$148.38M+2214.1%
2017$6.41M-22.4%
2016$8.26M-